Navigation Links
Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting

dividually (p=0.02 and p less than 0.001, respectively) and in the meta-analysis (p less than 0.001). In addition, average scores for all 12 individual questions in the MSWS-12 were better for timed walk responders in both studies.

Timed walk responders also showed significantly better SGI scores than non-responders in the meta-analysis (p less than 0.001) and in both studies individually (p=0.004 and p less than 0.001, respectively). The CGI was applied differently in the two studies, so the meta-analysis was not performed. It showed a strong trend in the retrospective analysis of the first trial (p=0.056) and significant improvement for responders versus non-responders in the second trial (p less than 0.001).

The validation of the consistent timed walk response criterion was consistent across the studies as well as in the patient subgroups examined. The subgroups included patients with all of the four major types of MS course as well as patients with a wide range of disability at baseline.

Andrew Goodman, M.D., Professor of Neurology, Chief, Neuroimmunology Unit, Director, Multiple Sclerosis Clinic at the University of Rochester Medical School said, "Walking impairment is one of the most common and critical problems for patients with MS, impacting a wide range of their activities. There are no therapies available today that are indicated for improving mobility in patients with MS. This meta-analysis found that the consistent improvement in walking speed on the Timed 25-Foot Walk represented clinically meaningful improvements for patients, as measured by three independent scales."

About Fampridine-SR

Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine, or 4-AP). Data collected in laboratory studies found that fampridine can improve the communication between damaged nerves, which may result in increased neurological function.

Fampridine-SR Mechanism of Action

'"/>




Page: 1 2 3 4

Related medicine technology :

1. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acorda Therapeutics Presents Fampridine Data ACTRIMS Meeting
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... for Cinryze for Acute HAE Indication is June 3, 2009 ... Incorporated (Nasdaq: VPHM ) today announced that the ... for Cinryze C1 Inhibitor (human) as a treatment for acute ... Application (sBLA), submitted to the FDA on December 1, ...
... CVS Caremark Proactive Pharmacy Care approach designed to help ... costs WOONSOCKET, R.I., Feb. 3 /PRNewswire/ ... (NYSE: CVS ) found that nearly half ... adherent to recommended drug therapies, significantly increasing their risk ...
Cached Medicine Technology:FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 6CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 2CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 3CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 4
(Date:4/18/2014)... have made a brain-related discovery that could revolutionize ... This discovery opens up the possibility that environmental ... specific brain activity that the researchers have identified ... Journal of Neuroscience has just published a ... associate professor of psychology and his doctoral student ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... , MONTGOMERY, Ala., ... LTCi Solutions from United of Omaha, a Mutual of Omaha company. ... products to suit producer,s sales needs - all of which offer ... on the first day of qualified need with no elimination period. ...
... , OREM, Utah, Dec. 9 LookingYourBest.com, ... Cosmetic and Plastic Surgeons , offers more than just a bold ... , The first aspect of the new LookingYourBest.com that will surely ... old, sterile layout with its pastel colors blending out to the ...
... , ARLINGTON, Va., Dec. 9 ... the Healthcare Distribution Management Association (HDMA), issued the following ... Patient Protection and Affordable Care Act, which would allow ... prescription drugs from foreign countries, as Senator Dorgan and ...
... ... , ... December 9, 2009 -- In 2008, LQ Performance Strategies predicted its core business, custom ... the economic climate deteriorated. At the same time, it recognized the opportunity to ...
... Web ... into likely employer compliance issues. , ... Minneapolis, MN (PRWEB) December 9, 2009 -- Ceridian Corporation, a ... filing and payroll outsourcing solutions, announced today it will present the first ...
... ... announce the launch of Educus ICD-9 Complete Reference – a ... the Apple iPhone, iPod touch, and Android-powered phones. The application provides ... the user can either search through all of the codes or the ...
Cached Medicine News:Health News:AIMS Benefit Solutions Offering Long-Term Care Insurance Featuring CASH-First(TM) from United of Omaha 2Health News:AIMS Benefit Solutions Offering Long-Term Care Insurance Featuring CASH-First(TM) from United of Omaha 3Health News:Your Online Resource For Plastic Surgery Information 2Health News:Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs 2Health News:LQ Performance Strategies Launches the LQ Solutions Vault Providing On Demand Strategic Corporate Training Products and Services 2Health News:LQ Performance Strategies Launches the LQ Solutions Vault Providing On Demand Strategic Corporate Training Products and Services 3Health News:Ceridian Web Forum to Prepare Employers for Health Care Reform 2Health News:Ceridian Web Forum to Prepare Employers for Health Care Reform 3Health News:Educus.com Launches ICD-9 app for Apple iPhone and Android Devices 2Health News:Educus.com Launches ICD-9 app for Apple iPhone and Android Devices 3
... The IsoFlex S lead's small ... ease implantation and lower the ... smaller, more tortuous vessels. Atrial ... and fixation options combine to ...
Unipolar Atrial "J" Lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: